Clinical trial
A Phase I Study of B43-Genistein Immunoconjugate in Recurrent B-Lineage Acute Lymphoblastic Leukemia and Non Hodgkin's Lymphoma
NCT00004858 is registered in ClinicalTrials.gov with Parker Hughes Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of B43-Genistein Immunoconjugate in Recurrent B-Lineage Acute Lymphoblastic Leukemia and Non Hodgkin's Lymphoma
- Lead sponsor
- Parker Hughes Cancer Center
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- March 31, 2000
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.